Ocular Therapeutix (NASDAQ:OCUL) Insider Nadia Waheed Sells 3,510 Shares

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Nadia Waheed sold 3,510 shares of the firm’s stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $7.74, for a total value of $27,167.40. Following the sale, the insider directly owned 314,907 shares of the company’s stock, valued at $2,437,380.18. This trade represents a 1.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Nadia Waheed also recently made the following trade(s):

• On Thursday, February 12th, Nadia Waheed sold 7,863 shares of Ocular Therapeutix stock. The stock was sold at an average price of $9.04, for a total value of $71,081.52.

Ocular Therapeutix Stock Up 6.4%

OCUL traded up $0.54 during midday trading on Tuesday, hitting $8.95. 6,321,431 shares of the company’s stock traded hands, compared to its average volume of 7,037,731. The company has a debt-to-equity ratio of 0.11, a current ratio of 15.39 and a quick ratio of 15.32. The company has a market cap of $1.95 billion, a PE ratio of -6.22 and a beta of 0.90. The stock’s fifty day simple moving average is $10.64 and its 200-day simple moving average is $11.64. Ocular Therapeutix, Inc. has a one year low of $5.78 and a one year high of $16.44.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. Ocular Therapeutix had a negative net margin of 511.90% and a negative return on equity of 70.68%. The firm had revenue of $13.25 million during the quarter, compared to analysts’ expectations of $16.13 million. During the same period in the prior year, the company posted ($0.29) earnings per share. Ocular Therapeutix’s revenue for the quarter was down 22.4% on a year-over-year basis. As a group, equities analysts anticipate that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ocular Therapeutix

Institutional investors have recently added to or reduced their stakes in the company. Pale Fire Capital SE grew its holdings in shares of Ocular Therapeutix by 20.7% during the 2nd quarter. Pale Fire Capital SE now owns 530,135 shares of the biopharmaceutical company’s stock worth $4,920,000 after purchasing an additional 90,748 shares in the last quarter. Saturn V Capital Management LP lifted its position in Ocular Therapeutix by 21.8% in the second quarter. Saturn V Capital Management LP now owns 728,576 shares of the biopharmaceutical company’s stock worth $6,761,000 after purchasing an additional 130,385 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in Ocular Therapeutix during the second quarter worth $342,000. Allianz Asset Management GmbH boosted its stake in Ocular Therapeutix by 63.2% during the second quarter. Allianz Asset Management GmbH now owns 61,200 shares of the biopharmaceutical company’s stock worth $568,000 after buying an additional 23,700 shares in the last quarter. Finally, Panagora Asset Management Inc. increased its holdings in Ocular Therapeutix by 33.6% in the 2nd quarter. Panagora Asset Management Inc. now owns 296,546 shares of the biopharmaceutical company’s stock valued at $2,752,000 after buying an additional 74,542 shares during the period. 59.21% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently commented on OCUL shares. Royal Bank Of Canada reissued an “outperform” rating and issued a $30.00 price target on shares of Ocular Therapeutix in a research report on Thursday, February 5th. Needham & Company LLC dropped their target price on shares of Ocular Therapeutix from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Friday. Citigroup reissued an “outperform” rating on shares of Ocular Therapeutix in a research report on Tuesday, February 17th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Ocular Therapeutix in a research report on Tuesday, February 17th. Finally, HC Wainwright boosted their price objective on Ocular Therapeutix from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $23.78.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.